Business
Travere Therapeutics Provides Corporate Update and 2025 Outlook
Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA target action date of August 28, 2025 Company remains on track to provide regulatory update on sparsentan in FSGS by its fourth quarter 2024 earnings call SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2024 to be approximately $74 million. For the fiscal year 2024, the Company expects net product sales to be approximately $227 million. The Company ended 2024 with approximately $371 million in cash, cash equivalents, and marketable securities. The Company also provided an update on key corporate, clinical, and regulatory development initiatives, including anticipated 2025 milestones. “The fourth quarter capped a tremendous year of execution for Travere. Following full approval of FILSPARI in September, the ongoing U.S. commercial launch resulted in nearly 700 new patient start forms in the fourth quarter as well as a 40% increase in FILSPARI net product sales compared to the third quarter,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “As we look ahead to the new year, we expect to help even more patients with IgAN through continued strong commercial execution, the final publication of the updated KDIGO guidelines and potential approval of the recently accepted sNDA to modify liver monitoring for FILSPARI. Beyond IgAN, we believe that sparsentan has the potential to become an important new medicine for people with FSGS, and we remain on track to provide an update on our interactions with FDA to establish a potential regulatory pathway for this additional indication by our fourth quarter 2024 earnings call.” Program Updates and Anticipated 2025 Milestones FILSPARI® (sparsentan) – IgA Nephropathy (IgAN) In the fourth quarter of 2024, the Company received 693 new patient start forms (PSFs), driven by growth amongst new and repeat prescribers following full approval by the U.S. Food and Drug Administration (FDA) on September 5, 202...